DBVT dbv-technologies.com: מקדם חוב לטווח ארוך להון

This daily price chart for DBV Technologies S.A. (DBVT) illustrates the performance of the company developing innovative Viaskin patches to combat food allergies, where the primary driver is FDA approval for the pediatric peanut drug. The environmental profile is based on bio-waste disposal in laboratories, and the current metric stands at 0.04. However, the risk of losing market share persists due to competition from simpler oral treatment methods.

By advancing patch technologies and optimizing international component logistics, DBV Technologies S.A. requires a precise balance between biolaboratory investments and debt load. An analysis of the long-term debt-to-equity structure allows for an assessment of the ratio of liabilities with maturities exceeding one year to equity, determining the company's ability to withstand operational shocks and the extent to which its financial stability depends on borrowed capital.